U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H16N6O.C4H6O5
Molecular Weight 490.4681
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEBIO-1347 (S)-HYDROXYSUCCINATE

SMILES

O[C@@H](CC(O)=O)C(O)=O.CC1=NC2=C(N1)C=C(C=C2)N3N=CC(C(=O)C4=CC5=C(N4)C=CC=C5)=C3N

InChI

InChIKey=NPJXUVSDQSNORN-WNQIDUERSA-N
InChI=1S/C20H16N6O.C4H6O5/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18;5-2(4(8)9)1-3(6)7/h2-10,25H,21H2,1H3,(H,23,24);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25169980

CH5183284/Debio 1347 is selective and orally available fibroblast growth factor receptors: FGFR1, FGFR2, and FGFR3 inhibitor that has a unique chemical scaffold. By interacting with unique residues in the ATP-binding site of FGFR1, FGFR2, or FGFR3, CH5183284/Debio 1347 selectively inhibits there receptors, but does not inhibit kinase insert domain receptor (KDR) or other kinases. CH5183284/Debio 1347 will provide therapeutic opportunities for patients who have FGFR genetic alterations and patients with acquired resistance to existing FGFR selective inhibitors that contain the common methoxy moieties.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
9.3 nM [IC50]
7.6 nM [IC50]
22.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1125 ng/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
425 ng/mL
30 mg 1 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2486 ng/mL
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2729 ng/mL
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
469 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
881 ng/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
114 ng/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1373 ng/mL
110 mg 1 times / day steady-state, oral
dose: 110 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
291 ng/mL
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14744 ng × h/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3551 ng × h/mL
30 mg 1 times / day steady-state, oral
dose: 30 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
41994 ng × h/mL
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
44185 ng × h/mL
150 mg 1 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4700 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
9567 ng × h/mL
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
973 ng × h/mL
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3910 ng × h/mL
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DEBIO-1347 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
2015 Dec
Patents

Sample Use Guides

Adaptive doses of Debio1347 (CH5183284): (10 mg to 210 mg/day) until the recommended dose is determined.
Route of Administration: Oral
MAPK pathway suppression by CH5183284/Debio 1347 in FGFR-altered cancer cell lines was investigated. Cells were treated with 1 μmol/L CH5183284/Debio 1347. It was confirmed that the ERK (GSE15417) and MEK signatures were suppressed by CH5183284/Debio 1347 only in sensitive cell lines harboring FGFR alterations. Consistent with this, suppression of phospho-ERK by a 2-hour treatment with CH5183284/Debio 1347 was observed in seven cancer cell lines harboring FGFR alterations.
Name Type Language
DEBIO-1347 (S)-HYDROXYSUCCINATE
Code English
BUTANEDIOIC ACID, 2-HYDROXY-, (2S)-, COMPD. WITH (5-AMINO-1-(2-METHYL-1H-BENZIMIDAZOL-6-YL)-1H-PYRAZOL-4-YL)-1H-INDOL-2-YLMETHANONE (1:1)
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/17/1916
Created by admin on Sat Dec 16 01:54:43 UTC 2023 , Edited by admin on Sat Dec 16 01:54:43 UTC 2023
Code System Code Type Description
FDA UNII
2SMH8D25J8
Created by admin on Sat Dec 16 01:54:43 UTC 2023 , Edited by admin on Sat Dec 16 01:54:43 UTC 2023
PRIMARY
PUBCHEM
131801095
Created by admin on Sat Dec 16 01:54:43 UTC 2023 , Edited by admin on Sat Dec 16 01:54:43 UTC 2023
PRIMARY
EVMPD
SUB192816
Created by admin on Sat Dec 16 01:54:43 UTC 2023 , Edited by admin on Sat Dec 16 01:54:43 UTC 2023
PRIMARY
CAS
1265231-80-8
Created by admin on Sat Dec 16 01:54:43 UTC 2023 , Edited by admin on Sat Dec 16 01:54:43 UTC 2023
PRIMARY